{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:53:11Z","timestamp":1789872791675,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009843","name":"South Australian Health and Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009843","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Government Research Training Program Stipend Scholarship"},{"name":"Cancer Council S"},{"name":"Hopwood Centre for Neurobiology"},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00018-021-03825-7","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T13:02:53Z","timestamp":1617886973000},"page":"4035-4052","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["TSC-insensitive Rheb mutations induce oncogenic transformation through a combination of constitutively active mTORC1 signalling and proteome remodelling"],"prefix":"10.1007","volume":"78","author":[{"given":"Jianling","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart P.","family":"De Poi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne K.","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Bruning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenru","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Selth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Sargeant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0704-6442","authenticated-orcid":false,"given":"Christopher G.","family":"Proud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"3825_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168:960\u2013976. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"key":"3825_CR2","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/0092-8674(92)90643-Q","volume":"69","author":"J Chung","year":"1992","unstructured":"Chung J, Kuo CJ, Crabtree GR, Blenis J (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 69:1227\u20131236","journal-title":"Cell"},{"key":"3825_CR3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/j.1460-2075.1996.tb00398.x","volume":"15","author":"L Beretta","year":"1996","unstructured":"Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N (1996) Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 15:658\u2013664. https:\/\/doi.org\/10.1002\/j.1460-2075.1996.tb00398.x","journal-title":"EMBO J"},{"key":"3825_CR4","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1073\/pnas.85.2.406","volume":"85","author":"P Jeno","year":"1988","unstructured":"Jeno P, Ballou LM, Novak-Hofer I, Thomas G (1988) Identification and characterization of a mitogen-activated S6 kinase. Proc Natl Acad Sci USA 85:406\u2013410. https:\/\/doi.org\/10.1073\/pnas.85.2.406","journal-title":"Proc Natl Acad Sci USA"},{"key":"3825_CR5","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1126\/science.1187532","volume":"328","author":"RJ Dowling","year":"2010","unstructured":"Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328:1172\u20131176","journal-title":"Science"},{"key":"3825_CR6","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1002\/j.1460-2075.1995.tb00257.x","volume":"14","author":"A Haghighat","year":"1995","unstructured":"Haghighat A, Mader S, Pause A, Sonenberg N (1995) Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 14:5701\u20135709","journal-title":"EMBO J"},{"key":"3825_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.277.5322.99","volume":"277","author":"GJ Brunn","year":"1997","unstructured":"Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC Jr, Abraham RT (1997) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99\u2013101","journal-title":"Science"},{"key":"3825_CR8","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1101\/gad.1110003","volume":"17","author":"K Inoki","year":"2003","unstructured":"Inoki K, Li Y, Xu T, Guan KL (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17:1829\u20131834","journal-title":"Genes Dev"},{"key":"3825_CR9","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/s1097-2765(03)00220-x","volume":"11","author":"A Garami","year":"2003","unstructured":"Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G (2003) Insulin activation of Rheb, a mediator of mTOR\/S6K\/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11:1457\u20131466. https:\/\/doi.org\/10.1016\/s1097-2765(03)00220-x","journal-title":"Mol Cell"},{"key":"3825_CR10","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/s0960-9822(03)00506-2","volume":"13","author":"AR Tee","year":"2003","unstructured":"Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13:1259\u20131268. https:\/\/doi.org\/10.1016\/s0960-9822(03)00506-2","journal-title":"Curr Biol"},{"key":"3825_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.tibs.2003.09.003","volume":"28","author":"BD Manning","year":"2003","unstructured":"Manning BD, Cantley LC (2003) Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 28:573\u2013576. https:\/\/doi.org\/10.1016\/j.tibs.2003.09.003","journal-title":"Trends Biochem Sci"},{"key":"3825_CR12","doi-asserted-by":"publisher","first-page":"10662","DOI":"10.1038\/ncomms10662","volume":"7","author":"C Demetriades","year":"2016","unstructured":"Demetriades C, Plescher M, Teleman AA (2016) Lysosomal recruitment of TSC2 is a universal response to cellular stress. Nat Commun 7:10662. https:\/\/doi.org\/10.1038\/ncomms10662","journal-title":"Nat Commun"},{"key":"3825_CR13","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik R, Harsha B, Kok CY, Jia M, Jubb H, Sondka Z, Thompson S, De T, Campbell PJ (2017) COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res 45:D777-d783. https:\/\/doi.org\/10.1093\/nar\/gkw1121","journal-title":"Nucleic Acids Res"},{"key":"3825_CR14","doi-asserted-by":"publisher","first-page":"19793","DOI":"10.1074\/jbc.C600028200","volume":"281","author":"L Yan","year":"2006","unstructured":"Yan L, Findlay GM, Jones R, Procter J, Cao Y, Lamb RF (2006) Hyperactivation of mammalian target of rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase. J Biol Chem 281:19793\u201319797. https:\/\/doi.org\/10.1074\/jbc.C600028200","journal-title":"J Biol Chem"},{"key":"3825_CR15","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.1038\/onc.2008.180","volume":"27","author":"H Jiang","year":"2008","unstructured":"Jiang H, Vogt PK (2008) Constitutively active Rheb induces oncogenic transformation. Oncogene 27:5729\u20135740. https:\/\/doi.org\/10.1038\/onc.2008.180","journal-title":"Oncogene"},{"key":"3825_CR16","doi-asserted-by":"publisher","first-page":"12195","DOI":"10.1074\/jbc.C113.543736","volume":"289","author":"MT Mazhab-Jafari","year":"2014","unstructured":"Mazhab-Jafari MT, Marshall CB, Ho J, Ishiyama N, Stambolic V, Ikura M (2014) Structure-guided mutation of the conserved G3-box glycine in Rheb generates a constitutively activated regulator of mammalian target of rapamycin (mTOR). J Biol Chem 289:12195\u201312201. https:\/\/doi.org\/10.1074\/jbc.C113.543736","journal-title":"J Biol Chem"},{"key":"3825_CR17","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/ijc.29707","volume":"138","author":"ME Armijo","year":"2016","unstructured":"Armijo ME, Campos T, Fuentes-Villalobos F, Palma ME, Pincheira R, Castro AF (2016) Rheb signaling and tumorigenesis: mTORC1 and new horizons. Int J Cancer 138:1815\u20131823. https:\/\/doi.org\/10.1002\/ijc.29707","journal-title":"Int J Cancer"},{"key":"3825_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/mt.2011.213","volume":"20","author":"SR Kim","year":"2012","unstructured":"Kim SR, Kareva T, Yarygina O, Kholodilov N, Burke RE (2012) AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth. Mol Ther 20:275\u2013286. https:\/\/doi.org\/10.1038\/mt.2011.213","journal-title":"Mol Ther"},{"key":"3825_CR19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/onc.2016.246","volume":"36","author":"Y Wang","year":"2017","unstructured":"Wang Y, Hong X, Wang J, Yin Y, Zhang Y, Zhou Y, Piao HL, Liang Z, Zhang L, Li G, Xu G, Kwiatkowski DJ, Liu Y (2017) Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth. Oncogene 36:756\u2013765. https:\/\/doi.org\/10.1038\/onc.2016.246","journal-title":"Oncogene"},{"key":"3825_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12885-017-3938-5","volume":"18","author":"JJ Heard","year":"2018","unstructured":"Heard JJ, Phung I, Potes MI, Tamanoi F (2018) An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. BMC Cancer 18:69. https:\/\/doi.org\/10.1186\/s12885-017-3938-5","journal-title":"BMC Cancer"},{"key":"3825_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cub.2019.01.029","volume":"29","author":"J Xie","year":"2019","unstructured":"Xie J, de Souza AV, von der Haar T, O\u2019Keefe L, Lenchine RV, Jensen KB, Liu R, Coldwell MJ, Wang X, Proud CG (2019) Regulation of the elongation phase of protein synthesis enhances translation accuracy and modulates lifespan. Curr Biol 29:737-749.e735. https:\/\/doi.org\/10.1016\/j.cub.2019.01.029","journal-title":"Curr Biol"},{"key":"3825_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"77","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 77:248\u2013254","journal-title":"Anal Biochem"},{"key":"3825_CR23","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41596-018-0014-9","volume":"13","author":"SJ Humphrey","year":"2018","unstructured":"Humphrey SJ, Karayel O, James DE, Mann M (2018) High-throughput and high-sensitivity phosphoproteomics with the EasyPhos platform. Nat Protoc 13:1897\u20131916. https:\/\/doi.org\/10.1038\/s41596-018-0014-9","journal-title":"Nat Protoc"},{"key":"3825_CR24","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1021\/acs.jproteome.9b00090","volume":"18","author":"DJ Harney","year":"2019","unstructured":"Harney DJ, Hutchison AT, Hatchwell L, Humphrey SJ, James DE, Hocking S, Heilbronn LK, Larance M (2019) Proteomic analysis of human plasma during Intermittent fasting. J Proteome Res 18:2228\u20132240. https:\/\/doi.org\/10.1021\/acs.jproteome.9b00090","journal-title":"J Proteome Res"},{"key":"3825_CR25","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1002\/ijc.31210","volume":"142","author":"J Xie","year":"2018","unstructured":"Xie J, Shen K, Lenchine RV, Gethings LA, Trim PJ, Snel MF, Zhou Y, Kenney JW, Kamei M, Kochetkova M, Wang X, Proud CG (2018) Eukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis. Int J Cancer 142:1865\u20131877. https:\/\/doi.org\/10.1002\/ijc.31210","journal-title":"Int J Cancer"},{"key":"3825_CR26","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.bbamcr.2017.06.011","volume":"1864","author":"LK Hein","year":"2017","unstructured":"Hein LK, Apaja PM, Hattersley K, Grose RH, Xie J, Proud CG, Sargeant TJ (2017) A novel fluorescent probe reveals starvation controls the commitment of amyloid precursor protein to the lysosome. Biochim Biophys Acta Mol Cell Res 1864:1554\u20131565. https:\/\/doi.org\/10.1016\/j.bbamcr.2017.06.011","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"3825_CR27","doi-asserted-by":"publisher","first-page":"18717","DOI":"10.1074\/jbc.M414499200","volume":"280","author":"EM Smith","year":"2005","unstructured":"Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 280:18717\u201318727","journal-title":"J Biol Chem"},{"key":"3825_CR28","doi-asserted-by":"publisher","first-page":"17895","DOI":"10.18632\/oncotarget.4963","volume":"6","author":"AP Ghosh","year":"2015","unstructured":"Ghosh AP, Marshall CB, Coric T, Shim EH, Kirkman R, Ballestas ME, Ikura M, Bjornsti MA, Sudarshan S (2015) Point mutations of the mTOR-RHEB pathway in renal cell carcinoma. Oncotarget 6:17895\u201317910. https:\/\/doi.org\/10.18632\/oncotarget.4963","journal-title":"Oncotarget"},{"key":"3825_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4","journal-title":"J Immunol Methods"},{"key":"3825_CR30","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.cd-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM (2014) A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov 4:554\u2013563. https:\/\/doi.org\/10.1158\/2159-8290.cd-13-0929","journal-title":"Cancer Discov"},{"key":"3825_CR31","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9207.1","author":"J Xie","year":"2016","unstructured":"Xie J, Wang X, Proud CG (2016) mTOR inhibitors in cancer therapy. F1000Res. https:\/\/doi.org\/10.12688\/f1000research.9207.1","journal-title":"F1000Res"},{"key":"3825_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann D, Park S, Hall MN (2018) mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer 18:744\u2013757. https:\/\/doi.org\/10.1038\/s41568-018-0074-8","journal-title":"Nat Rev Cancer"},{"key":"3825_CR33","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.bmcl.2013.01.019","volume":"23","author":"KG Pike","year":"2013","unstructured":"Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M (2013) Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 23:1212\u20131216. https:\/\/doi.org\/10.1016\/j.bmcl.2013.01.019","journal-title":"Bioorg Med Chem Lett"},{"key":"3825_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J (2018) Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer 18:533\u2013548. https:\/\/doi.org\/10.1038\/s41568-018-0038-z","journal-title":"Nat Rev Cancer"},{"key":"3825_CR35","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1128\/mcb.01457-14","volume":"35","author":"CE Moore","year":"2015","unstructured":"Moore CE, Mikolajek H, Regufe da Mota S, Wang X, Kenney JW, Werner JM, Proud CG (2015) Elongation factor 2 kinase is regulated by proline hydroxylation and protects cells during hypoxia. Mol Cell Biol 35:1788\u20131804. https:\/\/doi.org\/10.1128\/mcb.01457-14","journal-title":"Mol Cell Biol"},{"key":"3825_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/aps.2015.123","volume":"37","author":"R Liu","year":"2016","unstructured":"Liu R, Proud CG (2016) Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases. Acta Pharmacol Sin 37:285\u2013294. https:\/\/doi.org\/10.1038\/aps.2015.123","journal-title":"Acta Pharmacol Sin"},{"key":"3825_CR37","doi-asserted-by":"publisher","first-page":"12220","DOI":"10.1074\/jbc.M309773200","volume":"279","author":"GJ Browne","year":"2004","unstructured":"Browne GJ, Finn SG, Proud CG (2004) Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279:12220\u201312231. https:\/\/doi.org\/10.1074\/jbc.M309773200","journal-title":"J Biol Chem"},{"key":"3825_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"J Kim","year":"2016","unstructured":"Kim J et al (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1\u2013222. https:\/\/doi.org\/10.1080\/15548627.2015.1100356","journal-title":"Autophagy"},{"key":"3825_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","volume":"17","author":"DJ Klionsky","year":"2021","unstructured":"Klionsky DJ et al (2021) Autophagy 17:1\u2013382. https:\/\/doi.org\/10.1080\/15548627.2020.1797280","journal-title":"Autophagy"},{"key":"3825_CR40","first-page":"56","volume":"60","author":"E Racker","year":"1972","unstructured":"Racker E (1972) Bioenergetics and the problem of tumor growth. Am Sci 60:56\u201363","journal-title":"Am Sci"},{"key":"3825_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1042\/BJ20080281","volume":"412","author":"J Huang","year":"2008","unstructured":"Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412:179\u2013190. https:\/\/doi.org\/10.1042\/BJ20080281","journal-title":"Biochem J"},{"key":"3825_CR42","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/ncb996","volume":"5","author":"LJ Saucedo","year":"2003","unstructured":"Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D, Edgar BA (2003) Rheb promotes cell growth as a component of the insulin\/mTOR signalling network. Nat Cell Biol 5:566\u2013571","journal-title":"Nat Cell Biol"},{"key":"3825_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/ncb995","volume":"5","author":"H Stocker","year":"2003","unstructured":"Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P, Breuer S, Thomas G, Hafen E (2003) Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol 5:559\u2013565","journal-title":"Nat Cell Biol"},{"key":"3825_CR44","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/ncb999","volume":"5","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5:578\u2013581","journal-title":"Nat Cell Biol"},{"key":"3825_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature25023","volume":"552","author":"H Yang","year":"2017","unstructured":"Yang H, Jiang X, Li B, Yang HJ, Miller M, Yang A, Dhar A, Pavletich NP (2017) Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature 552:368\u2013373. https:\/\/doi.org\/10.1038\/nature25023","journal-title":"Nature"},{"key":"3825_CR46","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1038\/onc.2010.393","volume":"29","author":"MD Lacher","year":"2010","unstructured":"Lacher MD, Pincheira R, Zhu Z, Camoretti-Mercado B, Matli M, Warren RS, Castro AF (2010) Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene 29:6543\u20136556. https:\/\/doi.org\/10.1038\/onc.2010.393","journal-title":"Oncogene"},{"key":"3825_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.molcel.2010.05.007","volume":"38","author":"AY Choo","year":"2010","unstructured":"Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, Cantley LC, Blenis J (2010) Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 38:487\u2013499. https:\/\/doi.org\/10.1016\/j.molcel.2010.05.007","journal-title":"Mol Cell"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-021-03825-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T01:27:46Z","timestamp":1620437266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-021-03825-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3825"],"URL":"https:\/\/doi.org\/10.1007\/s00018-021-03825-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.09.05.284661","asserted-by":"object"}]},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"17 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal work was conducted in accordance with the National Health and Medical Research Council\u2019s Care and use of Animals for Scientific Purposes guidelines and with approval (No. SAM339) from the South Australian Health and Medical Research Institute\u2019s animal ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}